See more : Huhtamaki India Limited (HUHTAMAKI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Cognition Inc. (ACOGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Cognition Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JPMorgan Mid Cap Investment Trust plc (JMF.L) Income Statement Analysis – Financial Results
- Offerpad Solutions Inc. (OPAD) Income Statement Analysis – Financial Results
- Pathfinder Bancorp, Inc. (PBHC) Income Statement Analysis – Financial Results
- Marinus Pharmaceuticals, Inc. (MRNS) Income Statement Analysis – Financial Results
- Anova Metals Limited (AWV.AX) Income Statement Analysis – Financial Results
Alpha Cognition Inc. (ACOGF)
About Alpha Cognition Inc.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 86.03K | 87.32K | 89.09K | 85.75K | 0.00 | 0.00 |
| Gross Profit | -86.03K | -87.32K | -89.09K | -85.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.92M | 8.82M | 7.97M | 4.67M | 3.56M | 0.00 |
| General & Administrative | 4.50M | 4.53M | 3.40M | 950.71K | 391.47K | 0.00 |
| Selling & Marketing | 19.79K | 31.73K | 103.25K | 0.00 | 98.31K | 0.00 |
| SG&A | 4.71M | 4.56M | 3.51M | 950.71K | 1.52M | 32.46K |
| Other Expenses | 0.00 | 0.00 | -1.40M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Cost & Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Interest Income | 6.93K | 1.93K | 2.07K | 22.59K | 8.13K | 0.00 |
| Interest Expense | 68.95K | 172.88K | 528.16K | 770.37K | 0.00 | 0.00 |
| Depreciation & Amortization | 84.48K | 87.32K | 89.09K | 85.75K | 79.04K | 0.00 |
| EBITDA | -9.71M | -13.13M | -11.03M | -5.69M | -5.08M | -32.46K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.71M | -13.46M | -11.57M | -5.68M | -5.16M | -32.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.07M | 1.01M | -8.51M | -96.58K | -1.52M | 0.00 |
| Income Before Tax | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 172.88K | 528.16K | 770.37K | -78.45 | 0.00 |
| Net Income | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| EPS Diluted | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| Weighted Avg Shares Out | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
| Weighted Avg Shares Out (Dil) | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's Disease
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures...
Alpha Cognition Provides Business Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it's ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer's disease, commercialization strategy, and a...
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing,...
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a fourth closing pursuant to its previously announced private placement of units of the Company. Pursuant to the fourth closing,...
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed...
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of...
Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results...
Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing,...
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“Alpha Cognition” or the “Company”) announces that it has completed a second closing pursuant to its previously announced private placement of units of the Company. Pursuant to the second closing,...
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the submission of a New Drug Application (“NDA”) to the...
Source: https://incomestatements.info
Category: Stock Reports